Jill Elliott

Jill brings nearly 20 years of commercial experience in the biotech industry, with the last 6 years leading the commercialization of transformative gene and cell therapies for severe chronic diseases.  Jill is VP, Cell Therapy Commercialization at Novo Nordisk where she is shaping commercial strategy for their portfolio of cell therapies and is a member of the ARM Foundation Board of Directors.   Jill is passionate about bring next level therapies to high unmet communities and enjoys charting new paths to address the challenges associated with bringing new modalities to market.   Prior to her current role, she led the global marketing function at bluebird bio.  Jill earned her MBA from the Tuck School at Dartmouth College

Also Speaking

Lauren Shelton

Sharon Brownlow

Chief Business Officer • Cell and Gene Therapy Catapult

Daniel Teasley

Head of Viral & Gene Therapy Products and Services • MilliporeSigma

Event Info


Fun Run